DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/l8sxhx/global) has announced the addition of the "Global Tuberculosis Drugs Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tuberculosis Drugs market to grow at a CAGR of 6.75 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the outbreak of TB-HIV co-infections. The Global Tuberculosis Drugs market has also been witnessing the trend of increased focus on TB vaccine development. However, insufficient demand in developed countries could pose a challenge to the growth of this market. TechNavio's report, the Global Tuberculosis Drugs market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Tuberculosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Currently, the Bacille Calmette-Guerin (BCG) vaccine is the only vaccine for Tuberculosis (TB). It is inconsistent in protecting against the adolescent or adult form of TB, particularly pulmonary or … Continue reading →

A controversial pilot project reduced the cost of the most effective malaria drugs by giving manufacturers, such as Guilin Pharmaceutical in China, subsidies. A controversial pilot project reduced the cost of the most effective malaria drugs by giving manufacturers, such as Guilin Pharmaceutical in China, subsidies. One of the world's largest health funding agencies the Global Fund made two big decisions Thursday. The fund appointed Dr. Mark Dybul as its new executive director. Dybul is best known for leading the international fight against HIV during the Bush's administration through the President's Emergency Plan For AIDS. The fund's board also decided the fate of a controversial $225 million project that subsidizes the cost of the most effective malaria drugs in Africa. The fund says it will discontinue financial support for the Affordable Medicines Facility-malaria program, or AMFm, after a one-year transition period. Countries that wish to continue using subsidies will have to divert money from their regular malaria work to pay for them. There has been a vigorous debate in the global health community about AMFm. Advocates, such as Barry Bloom of Harvard School of Public Health, say the pilot project has reached its major goal. It's gotten the best malaria … Continue reading →

LONDON (Reuters) - Sanofi won the backing of European regulators for two new drugs against diabetes and cancer on Friday, a shot in the arm for the French company's drive to bring new products to market. New diabetes drug Lyxumia was recommended for treating type 2 diabetes and Zaltrap was endorsed for the treatment of advanced colorectal cancer, the European Medicines Agency (EMA) said. Recommendations from the EMA are normally endorsed by the European Commission within two or three months and Sanofi said it expected to hear from the Commission in the first quarter of 2013. Lyxumia, which Sanofi licensed from Denmark's Zealand Pharma, is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic's blood sugar level climbs too high. It is one of several new medicines Sanofi is banking on to drive growth after patent losses on former top-selling drugs. Pierre Chancel, Sanofi's global head of diabetes, said the positive opinion for Lyxumia was "an important milestone" and would help expand the company's already strong diabetes franchise, which is dominated by the long-acting insulin Lantus. Sanofi plans to submit Lyxumia for approval with the U.S. Food and … Continue reading →